梅特福林在牙科中的应用-一篇评论
Muhammad Khawaja Hammad Uddin1,2, Muhammad Shahrukh Khan Sadiq3, Ashfaq Ahmed1,3
1Department of Science of Dental Materials, Dr. Ishrat-ul-Ebad Khan Institute of Oral Health Sciences, Dow University of Health Sciences, Karachi, Sindh, Pakistan.
Journal of Taibah University Medical Sciences
|June 5, 2023
概括
甲胺,主要是治疗2型糖尿病的抗高血糖药物,在牙科中表现有前途. 研究强调其在牙周再生,植入物骨整合和口腔癌治疗方面的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 牙科研究 牙科研究
- 再生医学是一种再生医学.
背景情况:
- 甲福明是治疗2型糖尿病的关键口服抗高血糖药物.
- 新兴的研究表明,除了血糖控制之外,甲素的应用也多样化,特别是在口腔健康方面.
研究的目的:
- 审查目前关于甲福明在各种牙科应用中的潜在用途的研究.
- 突出梅特福林在牙周病,植入物学,牙科和口腔瘤学方面的潜力.
主要方法:
- 这是一篇叙事性综述,综合了最近临床试验和动物研究的发现.
- 文献搜索的重点是甲福明对牙周参数,干细胞分化,骨再生,骨整合和口腔癌的影响.
主要成果:
- 在糖尿病和牙周炎患者中,局部甲福明可以改善牙周参数.
- 甲胺促进了牙的分化,骨质母细胞活性和牙周骨的再生.
- 甲胺增强了植入物骨质整合,并在口腔状细胞癌上表现出抗癌作用.
- 动物研究表明,甲福明有助于正牙牙移动,并抵御器械腐蚀.
结论:
- 甲胺在多个牙科领域显示出作为辅助剂或治疗剂的巨大潜力.
- 它的再生,抗癌和骨质生成性质需要进一步研究临床牙科应用.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
219
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
219
Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Oral Hypoglycemic Agents: Sulfonylureas
250
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
250
Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K


